Patents by Inventor Yoshimasa Sakamoto
Yoshimasa Sakamoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10513561Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.Type: GrantFiled: January 11, 2017Date of Patent: December 24, 2019Assignees: National University Corporation Chiba University, Eisai R&D Management Co., Ltd.Inventors: Toshinori Nakayama, Motoko Kimura, Koji Hayashizaki, Toshifumi Hirayama, Jungo Kakuta, Yoshimasa Sakamoto, Ryu Gejima, Daisuke Tokita, Kenzo Muramoto, Toshio Imai
-
Publication number: 20190002588Abstract: The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.Type: ApplicationFiled: January 11, 2017Publication date: January 3, 2019Inventors: Toshinori Nakayama, Motoko Kimura, Koji Hayashizaki, Toshifumi Hirayama, Jungo Kakuta, Yoshimasa Sakamoto, Ryu Gejima, Daisuke Tokita, Kenzo Muramoto, Toshio Imai
-
Patent number: 9994816Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.Type: GrantFiled: May 4, 2015Date of Patent: June 12, 2018Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yuichi Ono, Toshio Imai, Yasuko Nakagawa
-
Patent number: 9969812Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.Type: GrantFiled: December 19, 2016Date of Patent: May 15, 2018Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Patent number: 9961278Abstract: The present disclosure relates to a solid-state image-capturing element and electronic device capable of improving the linearity of illuminance values. The dynamic-range expander 118 expands dynamic range of a pixel value for each pixel based on the pixel value having different exposure times of a plurality of pixels. The integrator 119 integrates pixel values having the dynamic range expanded by the dynamic-range expander 118 and generates an illuminance value. The present disclosure is applicable to complementary metal-oxide semiconductor (CMOS) image sensor or the like used in, for example, an illuminometer.Type: GrantFiled: October 10, 2014Date of Patent: May 1, 2018Assignee: Sony Semiconductor Solutions CorporationInventors: Yusuke Ikeda, Hideki Shoyama, Yoshimasa Sakamoto, Yuuichi Udou, Oichi Kumagai
-
Patent number: 9809647Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: August 3, 2015Date of Patent: November 7, 2017Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20170096493Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.Type: ApplicationFiled: December 19, 2016Publication date: April 6, 2017Applicant: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Patent number: 9527921Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.Type: GrantFiled: April 14, 2016Date of Patent: December 27, 2016Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
-
Publication number: 20160347858Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.Type: ApplicationFiled: April 14, 2016Publication date: December 1, 2016Applicant: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino
-
Publication number: 20160269659Abstract: The present disclosure relates to a solid-state image-capturing element and electronic device capable of improving the linearity of illuminance values. The dynamic-range expander 118 expands dynamic range of a pixel value for each pixel based on the pixel value having different exposure times of a plurality of pixels. The integrator 119 integrates pixel values having the dynamic range expanded by the dynamic-range expander 118 and generates an illuminance value. The present disclosure is applicable to complementary metal-oxide semiconductor (CMOS) image sensor or the like used in, for example, an illuminometer.Type: ApplicationFiled: October 10, 2014Publication date: September 15, 2016Applicant: Sony CorporationInventors: Yusuke Ikeda, Hideki Shoyama, Yoshimasa Sakamoto, Yuuichi Udou, Oichi Kumagai
-
Patent number: 9371389Abstract: An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.Type: GrantFiled: August 30, 2012Date of Patent: June 21, 2016Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshimasa Sakamoto, Miyuki Nishimura, Tetsu Kawano, Yukihisa Sawa, Toshio Imai
-
Publication number: 20160046707Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: August 3, 2015Publication date: February 18, 2016Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20150299654Abstract: The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.Type: ApplicationFiled: May 4, 2015Publication date: October 22, 2015Inventors: Yoshimasa Sakamoto, Yuichi Ono, Toshio Imai, Yasuko Nakagawa
-
Patent number: 9133273Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: June 21, 2013Date of Patent: September 15, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshio Imai, James Bradford Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 8932592Abstract: The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.Type: GrantFiled: October 28, 2010Date of Patent: January 13, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Miyuki Nishimura, Yoshimasa Sakamoto, Tetsu Kawano, Toshio Imai
-
Publication number: 20140193421Abstract: An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.Type: ApplicationFiled: August 30, 2012Publication date: July 10, 2014Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yoshimasa Sakamoto, Miyuki Nishimura, Tetsu Kawano, Yukihisa Sawa, Toshio Imai
-
Publication number: 20140045215Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: ApplicationFiled: June 21, 2013Publication date: February 13, 2014Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Patent number: 8604173Abstract: An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein.Type: GrantFiled: June 8, 2012Date of Patent: December 10, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Ono, Yoshimasa Sakamoto
-
Patent number: 8491901Abstract: The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.Type: GrantFiled: November 18, 2011Date of Patent: July 23, 2013Inventors: Toshio Imai, Brad Kline, Tetsu Kawano, Luigi Grasso, Yoshimasa Sakamoto, Jared Spidel, Miyuki Nishimura, Kenzo Muramoto, Tatsuo Horizoe
-
Publication number: 20120252021Abstract: An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein.Type: ApplicationFiled: June 8, 2012Publication date: October 4, 2012Applicant: EISAI R&D MANAGMENET CO., LTD.Inventors: Yuichi Ono, Yoshimasa Sakamoto